Introduction

Proton (1H) magnetic resonance spectroscopy (1HMRS) is available as an option by most manufacturers and is becoming a common adjunct to magnetic resonance imaging (MRI), especially for the differential diagnosis of intracranial lesions. Spectroscopy can also be performed on other elements having nuclei with nonzero quantum number, such as 13C and 31P. However, this requires additional equipment, while the proton (1H) magnetic resonance spectroscopy requires only a test phantom and a software package, making it simple and inexpensive addition to MRI systems. Magnetic resonance spectroscopy is the only method to obtain information about the biochemical composition of tissues in vivo.

Brain metabolites

N-acetylaspartat (Naa): 2.03 ppm (singlet) a neurotransmitter marker of intact and normal functioning of neurons, observed only in the brain parenchyma and neural tissue. In the normal brain parenchyma, its concentration depends on the density and functional activity of cells. All pathologocal processes, except for Canavan disease, lead to decreases of its concentration. In malignant neuroepithelial tumors its concentration is very low. In extra-axial tumors and metastases Naa is absent. However, the precise role of Naa remains unknown. Naa concentration is estimated at medium and long TE, at short TE metabolites of close resonant frequency can contribute to the Naa peak.

Choline (Cho): 3.21 ppm (singlet). Free choline, phosphocholine, and glycerophosphocholine give a single peak of total choline (tCho). Choline plays a role in the synthesis of phospholipids that make up cell membranes. Its concentration rises with their synthesis and destruction. Therefore, choline is a marker of cell density and membrane turnover. In tumors, demyelinating lesions and infarcts, its concentration increases. Choline to N-acetylaspartate ratio (Cho/NAA) is regarded as one of the most important indexes of malignancy.

Creatine/phosphocreatine (Cr/PCr): 3.05 ppm (singlet). It is impossible to separate their peaks on standard equipment therefore it is usually referred as total creatine (tCr). Creatine plays a role in energy metabolism, is present in neurons and in neuroglia, and regarded as an energy marker. Creatine is the most stable among normal metabolites – its concentration varies at different pathological processes to a lesser extent than concentrations of other brain metabolites. Nevertheless, its level usually grows in proportion to the degree of tumor malignancy, but tends to decrease when necrotic processes start to dominate.

Myo-inositol (Myo, M-Ins): 3.52 ppm (doublet of doublets, peaks determined only at short TE 20-30 ms) - six-fold alcohol of cyclohexane. Its exact role in metabolism is unknown, but it is considered a glial marker; as the concentration increases with glial proliferation. Myo-inositol is also regarded as a marker of demyelination. High concentrations of demyelinating lesions, inflammation and glial tumors. Glycine (Gly): 3.57 ppm (singlet peak reliably assessed at intermediate and long TE, at short TE merges with myo-inositol peak). This simplest of amino acids is considered an antioxidant. High concentrations observed in glioblastomas, primitive neuroectodermal tumors, ependymomas, and neurocytomas.

Glutamine / Glutamate (Gln + Glu = Glx): 2.10-2.60 ppm (multiplet peaks determined only at short TE 20-30 ms). Glutamate is a neurotransmitter involved in mitochondrial processes. Glutamine controls neurotransmitters. The resonant frequencies of the two metabolites are close, therefore, dividing their peaks on standard equipment is currently unfeasible. High levels of glutamine and glutamate can be observed in meningeomas.

Lactate (Lac): 1.31 ppm (doublet, inverted peak due to J-coupling at intermediate TE 135-140 ms). It is a marker of anaerobic processes. Normally present in low concentrations inspinal fluid. High concentrations observed in some tumors (both benign and malignant, but more often in the latter) in areas of acute ischemia and inflammatory processes. At short TE the lactate peak merges with the lipid peak, hence it is referred as lipid-lactate peak (Lac / Lip). Estimate lactate concentration is possible only using medium and long TE.

Lipids (Lip): 0.94 ppm; 1.33 ppm (singlet, usually peaks are
observed at short TE 20-30 ms) present in cell membranes, have short relaxation times. In normal brain parenchyma small peaks of free lipids can be observed only at very short TE. High concentrations of lipids indicate destruction and tissue necrosis. High peaks are observed in glioblastomas, lymphomas, metastases, subacute ischemic foci, tuberculous abscesses, sometimes in meningiomas. It’s important to note that scalp fat can lead to contamination of the voxel, especially when the region of interest (ROI) is close to the skull.

Alanine (Ala): 1.48 ppm (doublet, inverted peak due to J-coupling at intermediate TE 135-144 ms) - an amino acid whose role is not yet defined. Observed in meningiomas, pyogenic abscesses and glioblastomas. The resonant frequency is close to lactate (Lac - 1.31 ppm), so, their peaks may merge.

Acetate (Ac): 1.95 ppm (singlet) - product of the biochemical cycle of anaerobic microorganisms. Observed in pyogenic abscesses, empyema.

Succinate (Suc): 2.43 ppm (singlet) product of the biochemical cycle of anaerobic microorganisms. Observed in pyogenic abscesses, empyema.

Isoleucine (I-leu): 0.94 ppm, 1.01 ppm (multiplet, inverted peak due to J-coupling at intermediate TE 135-144 ms).

Leucine (Leu): 0.96 ppm, (multiplet, inverted peak due to J-coupling at intermediate TE 135-144 ms).

Valine (Val): 0.99 ppm (multiplet, inverted peak due to J-coupling at intermediate TE 135-144 ms).

Isoleucine, leucine, valine - amino acids (AA), high concentrations are observed in pyogenic abscesses and empyema. Since their resonant frequency coincides with the macromolecules (lipids and proteins), to assess their presence medium and long TE should be used.

Taurine (Tau): 3.25 ppm; 3.43 ppm (triplet) - organic acid, play role in osmoregulation, membrane stabilization. High concentrations of Taurine observed in primitive neuroectodermal tumors (PNET), including medulloblastomas, in pituitary adenomas and renal cell cancer metastases. At short TE peaks of taurine and myo-inositol can merge, at medium and long TE peaks have insufficient signal-to-noise.

Above were mentioned only the most important peaks for interpretation of the metabolite profile. Additional peaks listed in Table 1 [1].

Metabolite profiles in pathological brain processes

Demyelination: Multiple Sclerosis (MS): Demyelinating lesions occur in acute disseminated encephalomyelitis and nonspecific inflammatory process, but the most common cause is multiple sclerosis.

Multiple sclerosis is an autoimmune inflammatory disease of the central nervous system causing myelin damage of axonal membranes, leading to inflammation, demyelination, gliosis and axonal degeneration. According to the Poster’s criteria, in contrast to other episodes of demyelination, in multiple sclerosis dissemination of lesions is observed in time and space.

Table 1: Brain Metabolites; Configuration (multiplicity) of peaks.

| Metabolite | Chemical Shift δ (ppm) | Multiplicity |
|------------|------------------------|--------------|
| CH₃Isoluecine | 0.94 | t |
| CH₃Lip | 0.94 | m |
| CH₃Leucine | 0.96 | t |
| CH₃Valine | 0.99 | d |
| CH₄Isoluecine | 1.01 | d |
| CH₄Valine | 1.04 | d |
| CH₄Isoluecine | 1.26 | m |
| CH₄Lac | 1.31 | d |
| CH₄Lip | 1.33 | d |
| CH₄Isoluecine | 1.48 | m |
| CH₄Alanine | 1.48 | d |
| CH₄Lip | 1.50 | m |
| CH₄Leucine | 1.71 | t |
| CH₃Acetate | 1.95 | s |
| CH₄Isoluecine | 1.98 | m |
| CH₄NAA | 2.01 | s |
| CH₄Glu | 2.04 | m |
| CH₄Gln | 2.12 | m |
| CH₄Valine | 2.28 | m |
| CH₄Glu | 2.34 | m |
| CH₄Glu | 2.35 | m |
| CH₄Succinate | 2.43 | s |
| CH₄Gln | 2.46 | m |
| CH₂NAA | 2.49 | dd |
| CH₂Glu | 2.50 | m |
| CH₂NAA | 2.67 | dd |
| N(CH₃)₂Cr | 3.03 | s |
| N(CH₃)₂Cho | 3.19 | s |
| CH₃SO₂Taurine | 3.25 | t |
| H₂SM-Ins | 3.28 | t |
| NCH₂Taurine | 3.43 | t |
| (CH) 4M-Ins | 3.52 | dd |
| CH₂Glycine | 3.56 | s |
| CH₂Glu | 3.77 | t |
| CH₂Gln | 3.77 | t |
| CH₂Alanine | 3.79 | q |
| CH₂Cr | 3.91 | s |
| (CH₂)₂Cho | 4.05 | m |
| CH₂M-Ins | 4.05 | t |
| CH₂Lac | 4.10 | q |
| H₂O (37°) | 4.70 | s |

S: Singlet; d: Doublet; dd: Doublet of Doublets; t: Triplet; q: Quartet; m: Multiplet

Citation: Grabovetskyi S (2015) Proton Magnetic Resonance Spectroscopy of Focal Intracranial Lesions: Role in Clinical Practice. J Cancer Prev Curr Res 2(5): 00052. DOI: 10.15406/jcpcr.2015.05.00052
Depending on the course of the disease, the most recognized classification define benign (20%), relapsing-remitting (25%), second-progressive (40%) and primary-progressive (15%) forms of MS [2]. In the acute phase of demyelination, destruction of myelin membranes occurs, accompanied by inflammation. Subsequently, in the subacute and chronic phase remyelination and gliosis begin. In the acute stage of demyelination an increase of Cho (membrane destruction) and Lac (inhibition of aerobic metabolism), and marked decrease in NAA (damage or dysfunction of axons) is observed.

At short TE increased concentrations of Lip (degradation processes), Glu (excitotoxicity that is associated with the destruction of axons) and M-Ins (astrogliosis and glial proliferation) can be detected. After the acute phase transition, in affected areas normalization of concentrations of Lac, Cho and Lip, can be observed, while NAA may recover for several months [3]. Abnormal profile of metabolites can be found not only in areas of demyelination, but in white matter that appears normal on conventional MRI. A marked decrease in NAA, and increased concentrations of Lip, Glu and Cho in normal looking white matter can determine, with a high probability where in the future there new foci of demyelination may occur [3,4].

Some authors argue that chronic foci in various forms of MS can show differences in metabolite profiles. Thus, in relapsing forms, an increase of myo-inositol (M-Ins/Cr) and a significant reduction in N-acetylaspartate (NAA/Cr) can be observed, in contrast to the benign form of disease (Figure 1) [5].

**Figure 1:** Multiple sclerosis, PRESS, TE 30 ms spectrum of metabolites of chronic plaque (a) and normal looking white matter (b). High concentration of myo-inositol is suggestive of relapsing-remitting form of disease.

**Figure 2:** Chronic tumefactive demyelinating lesion in the right Corona radiata. PRESS, TE 30 ms(a, b) PRESS, TE 30 ms, PRESS, TE 135 ms (c, d). Spectra of the lesion (a, c) in comparison with normal brain parenchyma on the opposite side (b, d). At short TE, concentrations of the main metabolites in the lesion seem normal, marked by high peaks Lac/Lip 1.3 ppm and Lip/MM 0.9 ppm. At intermediate TE lactate peak is absent, there is only a slight decrease of NAA, Cho and Cr concentrations are normal. This “benign” metabolite profile helps rule out tumor.

Citation: Grabovetskyi S (2015) Proton Magnetic Resonance Spectroscopy of Focal Intracranial Lesions: Role in Clinical Practice. J Cancer Prev Curr Res 2(5): 00052. DOI: 10.15406/jcppr.2015.05.00052
Proton Magnetic Resonance Spectroscopy of Focal Intracranial Lesions: Role in Clinical Practice

Tumefactive demyelinating lesions on conventional MRI may be indistinguishable from intra axial tumors. In this case, MR spectroscopy can provide useful information (Figure 2). Although the metabolite profiles of demyelination lesions in the acute phase and tumors may be similar, in general, tumors show higher concentrations of choline and myo-inositol. Still there is no consensus among authors [6]. According to C. Majós et al. the ratio ≥ 0.9 of M-Ins/NAA and ≥ 1.9 CHO/NAA is strongly suggestive for tumors [7]. According to other studies, the only reliable criterion in differentiating tumors from demyelinating lesions NAA/Cr ratio in the central areas of lesions. For demyelinating lesions average NAA / Cr ~2.4, for gliomas~0.9 [8].

The role of spectroscopy:

1. Differentiation tumefactive demyelinating lesions from tumor (metabolite profiles of demyelination lesions in the acute phase and a low grade intra axial tumors can be virtually identical, a reliable criterion does not exist).

2. Defining forms of MS (yet mostly of academic interest).

Ischemia: Ischemic stroke or infarction is an acute cerebrovascular accident due to a deficiency of arterial blood flow of the brain, leading to hypoxia and development areas of necrosis. It mainly develops due to occlusion of arterial vessels. The variation in metabolite profile over time gives valuable information for the diagnosis and prognosis of the disease. In the acute phase of infarction its core shows signs of anaerobic metabolism and cell death. Accordingly, spectra from the affected areas are characterized by a high lactate peak, often in combination with significant lipid peaks (Figure 3). Lactate in low concentrations, can also be detected in “penumbra”, the area surrounding the core of ischemia. Lactate remains during few weeks the in the affected area.

The slow decrease of NAA concentration in the affected tissue during several days, which can occur even weeks after onset, can't be explained only by destructive action of enzymes on NAA. So, it was suggested, that it is caused by ongoing Ischemia in the affected area. This also may explain the presence of lactate in the core of ischemia in the subacute phase [9]. This has important diagnostic value for prognosis, and further treatment (Figure 4).

Cho level may either increase or decrease in areas of ischemia in the acute and chronic phases [10]. Higher concentration of Cho can be explained by gliosis and myelin membranes damage, while its decrease is a result of edema, necrosis and cell death [11].

Figure 3: Super acute infarction. PRESS, TE 30 ms (a) PRESS, TE 135 ms (b) marked decrease in NAA and myo-inositol. High lactate peak.

Figure 4: Infarction, sub acute phase. PRESS, TE 30 ms (a) TE 135 ms (b), lactate concentration map (c) and choline concentration map (d) marked decrease in NAA and myo-inositol (b), the high peaks of lactate and lipids. The map shows that the maximum concentrations of lactate and choline coincide topographically.
At the core of ischemia PCr rapidly converts to Cr [12]. The level of total creatine (tCr - Cr / PCr) decreases immediately after the onset, and this decline can be observed for 10 days. Muñiz et al. [10] reported continuous reduction of Cr levels over a period of three months from the stroke onset [10]. Estimation of the metabolite profile in the ischemic focus compared with the opposite side as a reference can lead to mistakes, as in a stroke the whole brain metabolism is disturbed [13].

**Role of spectroscopy:**

1. Study of biochemical processes in the development of ischemia for choosing treatment strategy (mainly academic interest).
2. Differential diagnosis with other focal lesions (in most cases, infarcts do not require differential diagnostics using spectroscopy).

**Neuroinfection: abscess, empyema:** Brain abscesses are focal accumulations of pus surrounded by a capsule, developed from localized infection in the brain parenchyma (cerebritis). Subdural empyemas are accumulations of pus in the subdural space, which sometimes occur as complication of inflammation of the meninges (meningitis). Microorganisms that lead to the formation of abscesses are diverse and often include mixed culture: aerobic, anaerobic, facultative aerobic and facultative anaerobic bacteria.

Spectroscopy of pyogenic brain abscess and empyema demonstrate presence of specific metabolites such as succinate, acetate, alanine, valine, leucine, isoleucine, lactate and lipids, which makes it possible to differentiate them from other brain cystic lesions (Figure 5 & 6). High levels of lactate, acetate and succinate can be explained by increased glycolysis and fermentation of microorganisms. Such amino acids, as valine and leucine are the final product of proteolysis by enzymes released by neutrophils in pus [14]. Neurons in abscesses are absent, so peaks of NAA and Cr should not be detected. The presence of these peaks can be explained only by misplaced voxels, or its contamination from adjacent parenchyma. Also, an acetate peak, which is close to NAA resonance frequency (Ac - 1.95 ppm, NAA - 2.01 ppm), can be erroneously attributed to the latter. Cho is also absent in the abscess cavity, since the necrotic core lacks membranes.

TBC abscesses are characterized by dominant lipid peaks and the presence of Cho. The presence of cytolytic amino acids have not been observed [15]. The results of spectroscopy in differential diagnosis between purulent abscesses and necrotic tumors are not always unambiguous, but the presence of the abovementioned amino acid peaks undoubtedly testifies to the abscess (Figure 5 & 7). Note that in chronic abscesses after drug treatment peaks of amino acids cannot be detected [16].
Proton Magnetic Resonance Spectroscopy of Focal Intracranial Lesions: Role in Clinical Practice

Role of spectroscopy:

1. Differentiation between tuberculosis and purulent abscesses.

2. Differentiation between abscesses and necrotic tumors (in chronic abscesses amino acids can be absent).

Meningiomas and other extra axial tumors:

Meningiomas constitute 15-20% of all intracranial tumors. According to the WHO classification there are three main types:

1) Typical or benign (grade I)
2) Atypical (grade II)
3) Anaplastic / malignant (grade III)

Most meningiomas have typical radiological features: distinct extra axial localization (CSF rim), involvement of the meninges (dural tail) etc. But in some cases they must be differentiated from other tumors with similar features. First of all, with other extra-axial tumors: neurinomas (cerebellopontine angle localization), pituitary adenomas (parasellar localization), hemangiopericytomas (meningeal tumors of mesenchymal, non-meningeoendotelial origin, which in most cases do not differ from meningiomas on conventional MRI), and meningeal metastases.

Intra axial (neuroepithelial) tumors with superficial or intraventricular localization may also require differential diagnosis with meningiomas. Namely choroid plexus tumors (choroid plexus papilloma, choroid plexus carcinoma).

Meningiomas, like other extra cerebral tumors do not originate in the brain parenchyma, so they do not contain NAA. The presence of a peak at the resonant frequency close to 2.0 ppm, which is often observed in spectroscopy of meningiomas, may be explained by voxel contamination, and possible presence of endogenous N-acetyl compounds (NACs): N-acetylaspartylglutamat and N-acetylgalactosamin [17]. Interestingly, the peak at 2.0 ppm was detected in the sinus mucocele. Andre et al. suggested this peak may be caused by the presence of N-acetyl glycoproteins [18]. In our observations of 25 meningiomas, the peak NAA, which was significantly higher than noise level, was never detected when using intermediate TE's. The typical spectra of meningiomas shows a high concentration of Cho and low Cr. Cho/Cr ratio in meningiomas is higher than in gliomas and metastases [19]. Lactate and lipids in meningiomas may be present in different concentrations. Alanine (doublet, 1.48 ppm), is considered to be a marker of meningiomas by many authors [20,21]. However, while its resonant frequency is close to lactate (doublet, 1.33 ppm) their peaks may merge. Also, both metabolites have inverted peaks at intermediate TE 135 - 144 ms. In practice alanine is detected in less than 50% meningioma cases [17]. (In our studies, a clear peak of alanine, separate from the lactate was determined in 5 cases out of 25).

New studies that focus on glutamine/glutamate (2.05 - 2.6 ppm), and glutathione (2.95 ppm) peaks, convincingly demonstrate a high concentration of these metabolites (associated with metabolic cycle of alanine) in meningiomas [22-25] (Figure 8). In our studies, all 25 (100%) meningiomas demonstrated a dominant concentration of the glutamine/glutamate complex.

Kousi et al. [26] found a typical chemical compounds for meningiomas that can be detected at 3.8 ppm using short TE, as a "distinct peak" (Figure 8). In vitro studies suggest that the "distinct peak" is likely to consist of the sum of resonant frequencies of phosphoethanolamine, alanine, glutamine and glutamate [23]. (In our study, in 24 of 25 of meningiomas a "distinct peak" was clearly present).

Attempts of some authors to discriminate the degree of anaplasia of meningiomas by concentrations of such metabolites as glutamine/glutamate complex, glutathione [24], and lipids [25], did not give convincing results yet [26].

Suprasellar tumors

Pituitary adenoma and craniofaringioma are the most common tumors of this localization. In most cases it is technically difficult to obtain quality spectra of metabolites in this area, especially for small tumors. So, there is little data in the literature.

Adenoma, originating from the adenohypophysis does not contain N-acetylaspartate, as well, as other extra cerebral tumors. Chernov et al. [27] describe the "substantial reduction of NAA" in adenomas [27]. In our studies, 4 of 5 adenomas showed an
evident peak at 2.0 ppm using intermediate TE (in the other extra axial tumors this peak at intermediate TE was absent or barely rose above the noise level). Perhaps, in adenomas this peak corresponds to other N-acetyl compounds, such as N-acetyl glycoproteins (Figure 9). Creatine can be found in a very low concentration or absent [28]. The concentration of choline may be relatively high, also sometimes can be observed peaks of lactate and lipids [29].

Figure 8: A typical metabolite profile of meningioma. PRESS TE 30 ms (a), PRESS TE 135 ms (b). Alanine peak (1.5 ppm) partially merge with those of lactate (a,b). The dominant peaks of Glx (a). High choline peak. “The distinct peak” *(a) also can be seen on the spectra, obtained with TE 135 ms at 3.8 ppm (b).

Figure 9: Spectra of pituitary adenoma. PRESS TE 30 ms (a), PRESS TE 135 ms (b) in comparison with suprasellar meningioma. PRESS TE 30 ms (c), PRESS TE 135 ms (d). Peak at 2.0 ppm in the spectra of adenoma, corresponding to NAA resonant frequency, is evident on both short (a) and Intermediate (b) TE. High peak myo-inositol at 3.58 ppm is present (a) there are no peaks of alanine and lactate, and low concentrations of glutamine/glutamate complex (a).
Cranioopharyngiomas - tumors originating from craniopharyngeal channel. There are two types of such tumors - adamantinomatous and papillary craniopharyngiomas. The first type occurs mainly in children, the second - in adults. Adamantinomatous craniopharyngiomas almost always have cystic component of significant size and multiple calcifications in a solid part. For papillary craniopharyngiomas calcifications are not typical and cysts are usually smaller.

Some authors state that in the spectrum of craniopharyngiomas peaks of metabolites are absent, but there are additional peaks caused by the presence of calcifications and microcysts [27]. Others describe peaks corresponding to resonance frequencies of lipid and lactate [29]. Probably the first describe spectra obtained from the solid part (no peaks of metabolites), and the latter describe spectra of the cystic part of the tumor (lipids and lactate peaks). Histological analysis confirmed the presence of cholesterol and lactate incysts (Figure 10).

**Schwannomas (neurinomas)**

Neurinoma account about 8% of all intracranial tumors, and 85% of tumors of cerebellopontine angle localization. Often they have to be differentiated from meningioma. As in the case of tumors of suprasellar localization, it is technically difficult to obtain quality spectra of metabolites in this area for small size tumors. Yoshida et al. state that in the spectra of neurinoma, the creatine peak is absent, choline is present, but to a lesser concentration than in meningiomas, and it shows the highest concentration myo-inositol of all intracranial tumors [28]. Also, in spectra of neurinomas can be observed lipid and lactate peaks (Figure 11).

**Hemangiopericytoma** are malignant meningeal mesenchymal tumors, found in the same locations, as meningioma, and often have the same features on the conventional MRI

The metabolite profile of hemangiopericytoma, like of the most other extra axial tumors shows high levels of choline, creatine and lack of N-acetylaspartate. Unlike meningiomas, the level of the glutamine/glutamate complex is not high, alanine is not recognized, a "distinct peak" at 3.8 ppm is absent. Instead, hemangiopericytomas show high peaks at 3.56 ppm, and 3.4 ppm, attributed to myo-inositol/glycine, and glucose, respectively, by some authors [30,31]. However, according to Young-Dae Cho et al. [32] these peaks should be classified as resonant frequencies.
of the “unknown molecule” because; in contrast to myo-inositol and glucose (that have T2 within 110 ms) both of these peaks are observed at long T2 [32]. However, it is not clear, why glycine, which has the same resonant frequency as myo-inositol (3.56 ppm), and long T2, was not mentioned by the authors (Figure 12).

**Intraventricular choroid plexus tumors (choroid plexus papilloma, choroid plexus carcinoma)**

Choroid plexus papilloma and choroid plexus carcinoma are rare neuroepithelial tumors. Accordingly, there is little data in literature on their metabolic profiles. They should be differentiated from other tumors of this localization, especially with meningiomas, as well as oligodendrogliomas and central neurocytomas. Papilloma, as carcinoma show two dominant peaks: myo-inositol and choline. Ratio of choline and myo-inositol corresponds to the degree of malignancy: namely choline levels are higher in carcinomas. In addition, carcinoma may contain lactate. Peaks of creatine and N-acetylaspartate is absent in choroid plexus tumors.

Metastases account for about 50% of all intracranial tumors. Solitary metastases first of all, should be differentiated with glioblastomas. But some of them, of superficial or meningeal localization, have the same radiological features as meningiomas. In this case spectroscopy plays an important role in differential diagnosis. The metabolite profile of metastases is characterized by two dominant peaks: choline and lipids at 1.3 ppm. Lipids in metastases of certain origin (lung cancer, etc.) can have long T2. Thus, the spectra obtained with TE 135 ms may show a positive peak at 1.3 ppm, instead of the inverted lactate doublet (Figure 13). Multiplets of the glutamine/glutamate complex are also sometimes observed, but not dominant as in meningiomas. Alanine and its “distinct peak” at 3.8 ppm are absent. The level of creatine is low, peak NAA, as in other extra axial tumors is missing [32]. Metabolic profiles of metastases and glioblastoma have much in common [33] but according to some authors, there are some differences [19,34] which will be covered in more detail in the discussion of the differential diagnosis of intra axial tumors.
Role of spectroscopy

Differential diagnosis between meningioma and other extra axial tumors. Namely, considering location and metabolite profile of tumors discrimination can be performed with high precision. With small size tumors quality spectra can't be obtained.

Attempts to determine the degree of malignancy of meningiomas (due to insufficient material in the literature, consensus among authors does not exist).

Gliomas and other intra axial tumors

I. Gliomas are a heterogeneous group of tumors that develop from glia. Gliomas account for approximately 30% of all intra cerebral tumors and 30% of all malignant brain tumors. They are histologically divided into astrocytoma, oligodendrogloma, ependymoma, and tumors of mixed origin - oligoastrocytomas. The most common are astrocytomas.

By the degree of malignancy gliomas are divided into 4 groups.

a) Benign, not invasive gliomas (grade I) include pilocytic astrocytoma, giant cell subependymal astrocytoma. These tumors do not tend to malignancy.

b) Relatively benign (grade II), include diffuse astrocytoma, oligodendroglia and ependymoma - tumors that tend to malignancy.

c) Malignant (grade III), include anaplastic astrocytoma, anaplastic oligodendroglia and anaplastic ependymoma.

d) Highly malignant (grade IV) is represented mainly by glioblastoma, which differ from anaplastic astrocytomas by large necrotic changes.

The general rule for metabolite profile of all gliomas is reduction of N-acetylaspartate (a marker of neuronal integrity) and increased levels of choline (a marker of cellularity, and membrane turnover), proportional to the degree of malignancy of tumors (Figure 14). But there is an exception of the rule. The most common of benign tumors, pilocytic astrocytoma (grade I), usually shows a very “aggressive” metabolite profile, with a significant reduction of NAA, high level of lactate and relative increase of choline (Figure 15). According to Hwang et al. the typical rate of main metabolites of pilocytic astrocytomas is Cho/NAA - 3.40, Cho/Cr - 3.46. The main difference between the profiles of pilocytic astrocytoma and malignant neuro epithelial tumor is the absence of a dominant lipid peak [35].

Citation: Grabovetskyi S (2015) Proton Magnetic Resonance Spectroscopy of Focal Intracranial Lesions: Role in Clinical Practice. J Cancer Prev Curr Res 2(5): 00052. DOI: 10.15406/jcpcr.2015.05.00052
The ability to differentiate histological types of gliomas, by means of the spectroscopy, most authors consider questionable [36,37,19]. Although others argue that metabolite profile of oligodendroglioma and ependymoma differ from that of astrocytoma. Rijpkema et al. [38] and colleagues insist that oligodendroglioma shows higher Glx concentrations using a short TE [38], Majos et al. [39] and colleagues write that the high peaks of myo-inositol/glycine (3.56 ppm) in ependymoma help differentiate it from other gliomas [39].

Currently spectroscopy is used for determining the degree of malignancy of gliomas, as it affects treatment strategy. According to Kousi et al. [26] the most sensitive and specific criteria for differential diagnosis between relatively benign (grade II) and malignant gliomas (grade III - IV) is the Cho/NAA ratio using an average TE and Cho/Cr ratio using short TE [26].

The average ratio of Cho/NAA is 2.02 for benign, and 2.93 for malignant tumors. The average ratio of Cho/Cr is 1.52 for benign, and 1.90 for malignant tumors.

Since malignant gliomas have a greater tendency to invasion than benign ones, according to the same authors, spectroscopy of peritumoral area is very important. The average ratio of Cho/NAA in peritumoral area is 0.83 for benign, and 1.22 for malignant tumors. The average ratio of Cho/Cr is 0.79 for benign, and 1.00 for malignant tumors [40]. This data is consistent with observations of other authors [41,42,33].

It is important to note, that in necrotic areas the level of all main metabolites including choline, tends to decline. So, glioblastomas can show either high or low choline concentration (Figure 16 & 17) [19]. Necrosis leads to a significant increase of lipids and macromolecule concentration. Thus, the dominant lipid peaks can be used as a marker of glioblastoma in differential diagnosis with anaplastic gliomas. In our own observations 6 of 23 glioblastomas, had low concentrations of choline, while areas with the lowest choline level were in the center of the tumor, while periphery, and peritumoral area showed its relative increase. All 6 glioblastomas with low choline concentration had dominant lipid peaks.

Lactate, unlike lipids, can be observed in gliomas of different degrees of malignancy [43]. Its peak merges with the peak of lipids using short TE, but can be separated while using intermediate TE due to peak inversion (it is true for 1.5 T system; at 3 T system, lactate peak in most cases fail to invert) [44]. Therefore, in the analysis of the spectra obtained using short TE, the peak at 1.3 ppm is referred as “lipid-lactate” - LL.

![Figure 16: Glioblastoma with high Cho concentration. PRESS, TE 30 ms (a) and PRESS, TE 135 ms (b). The dominant peak at 1.3 ppm, using TE 30 ms (a) is almost entirely contributed by lipids as the inverse lactate peak at TE 135 ms (b) only slightly rises above the noise level.](image1)

![Figure 17: Glioblastoma with low Cho concentration. PRESS, TE 30 ms (a) and PRESS, TE 135 ms (b). The dominant peak at 1.3 ppm, (a) is due to the presence of lipids with long T2 - a positive phase both at TE 30 ms (a), and at TE 135 ms (b).](image2)
An increase of the myo-inositol level is typical for gliomas. The highest level of myo-inositol shows a relatively benign (grade II) astrocytoma. According to Riyadh et al. [45] the average value of Myo/Cr is 0.49 for benign and 0.33 to 0.15 for anaplastic glioblastoma [45,46]. Spectroscopy also provides clinically valuable information for planning stereotactic biopsy (Figure 18), in evaluation of perifocal areas after invasive tumor removal, for radiation therapy planning (Figure 19), and in discrimination between radionecrosis and tumor recurrence (Figure 20). In all these cases, the highest concentration of choline (Cho/NAA and Cho/Cr ratio) is estimated.

In the differential diagnosis between radionecrosis and recurrent glioma, it is important to remember that during 4 months after irradiation brain parenchyma may exhibit high levels of choline [47]. According to Schlemmer et al. [48] for recurrent tumor average values are: Cho/NAA 3.44, Cho/Cr 2.30, while for areas of necrosis: Cho/NAA 1.29, Cho/Cr 1.20 [48].

In addition to determining the degree of malignancy of gliomas, they have to be differentiated from other intra axial masses. Benign gliomas - with tumefactive demyelinating lesions; malignant gliomas (especially glioblastoma) - with cerebral metastases, lymphoma and medulloblastoma.

II. Cerebral metastases on MRI images could be indistinguishable from glioblastoma. Differential diagnosis has important clinical significance for treatment planning. This issue has been the subject of many MRS studies. Several authors insist that differential diagnosis is not possible, because metastases and glioblastoma have similar metabolite profiles - with dominant lipid peaks, a high concentration of choline, low creatine levels and a significant reduction or absence of N-acetyl aspartate [19,33]. Möller-Hartmann et al. [49] state, that metastases have higher levels of lipids, compared to gliomas [49]. Attempts by various authors to differentiate glioblastomas from metastases by Cho/Cr ratio gave opposite results [50,51].

Most authors agree that the examination of the peritumoral zone has greater value for differential diagnosis [52,53]. Unlike glioblastomas, ration of Cho/NAA and Cho/Cr in the peritumoral area of metastases is close to those in normal parenchyma (Figure 21).

Figure 18: Bilateral thalamic astrocytoma. PRESS, TE 30 ms (a) and PRESS, TE 135 ms (b) and map of myo-inositol (c) and choline (d) concentrations, for planning stereotactic biopsy. Histological analysis revealed anaplastic astrocytoma, though high myo-inositol concentration is more typical for grade II gliomas.
Figure 19: Maps of Cho concentrations in patients after removal of anaplastic astrocytoma without evidence of tumor invasion (a), and glioblastoma, with evidence of tumor invasion in the perifocal area (b).

Figure 20: Partial removal, and radiation therapy of glioblastoma of the right hemisphere PRESS, TE 135 ms (a) and concentration Cho map (b). Tumor recurrence is evident in the opposite hemisphere.

Figure 21: Two hemorrhagic foci in the left hemisphere; discrimination between glioblastoma and metastasis. SWI (a) and concentration Cho map (b). High choline levels in peritumoral area are in favor of multifocal glioblastoma.
III. Primary central nervous system lymphomas account 1% of all intracranial tumors. Lipomas typically show low diffusivity and active contrast enhancement. On MRI images they may not differ from gliomas. There are no significant differences in metabolite profiles between malignant gliomas and lymphomas either. On spectroscopy, lymphomas show a high concentration of choline, low concentration of creatine, and a significant reduction or absence of N-acetylaspartate. Although there is no necrosis in lymphomas, according to Chawla et al. [54] the lipid-lactate peak may be even higher than in glioblastomas [54] (Figure 22). High concentrations of lipids are explained by macrophage accumulation. According to the same authors, due to the infiltration of lymphocytes and macrophages beyond the tumor borders, the peritumoral zone of lymphomas may show a characteristic profile of metabolites. Except for high values of Cho/Cr, which also applies to peritumoral area of glioblastomas, for lymphoma, increased lipid and lactate concentration in peritumoral zone is typical (the ratio Lip+Lac/Cr for lymphomas higher than for glioblastomas) [54].

IV. Medulloblastomas belong to primitive neuroectodermal tumor (PNET), localized in the cerebellum. Medulloblastomas are more common in children and affect cerebellar vermis. In adults, these tumors are usually localized in the cerebellar hemispheres. Medulloblastomas have high cell density, which manifests in restriction or diffusion on DWI and high levels of choline on MRI spectroscopy. In their in vitro studies, Kinoshita and Yokota found that medulloblastomas show a much higher concentration of taurine than other intracranial tumors [55]. Accordingly, other authors suggested to use taurine peak (3.43 ppm) as a marker of medulloblastomas in spectroscopy in vivo [56,57]. Majós et al. [58] state that medulloblastomas demonstrate higher concentrations of choline than gliomas of all grades of malignancy, and lower concentrations of lipids, compared with glioblastoma. The taurine peak was not accepted in their analysis as a reliable marker; because it did not rise significantly above the noise level. In our studies (4 medulloblastomas) 3 of 4 showed a small peak, suggestive of ataurine triplet (Figure 23).

Figure 22: Lymphoma of the corpus callosum. PRESS, TE 30 ms (a) and PRESS, TE 135 ms (b). The dominant lipid peaks at 1.3 ppm and 0.9 ppm (a). The inverse lactate peak using TE 135 ms barely rises above the noise (b).

Figure 23: PRESS, TE 135 ms. Medulloblastoma (a) and glioblastoma (b) low peak at 3.4 ppm, which may correspond to taurine triplet (*) can be found on the spectra of both tumors.
Role of spectroscopy

1) Differential diagnosis between gliomas and other intra axial tumors (metabolite profiles of tumors of various histological types can be similar: Analysis of the distribution of metabolites in tumor and peritumoral area may provide additional information).

2) Determine the degree of malignancy of gliomas.

3) Mapping metabolites for planning stereotactic biopsy, radiotherapy and surgery.

4) Differential diagnosis between tumor recurrence and radiation necrosis.

Conclusion

1H-MRS is a valuable tool in solving difficult neurological cases, especially in discrimination focal intracranial lesions; however, it should be always considered a supplementary tool to other examinations and conventional MRI when reaching the final diagnosis.

In the analysis of the spectra it is important to remember: the Cho/Cr and Cho/NAA ratio at short TE is lower than at intermediate TE, while the LL/Cr ratio is higher. In discriminating focal intracranial lesions, ideally both short and intermediate TE should be used. While spectra obtained using short TEs provide information about wider range of metabolites, spectra at intermediate TE make it possible to estimate the concentration of NAA much more accurately, and discriminate metabolites with the same resonant frequencies but different T2, such as lipid/lactate, and myo-inositol/glycine. Analysis of the distribution of metabolites in affected tissue, and perifocal area provides additional valuable information.

References

1. John Lindon (2000) Encyclopedia of Spectroscopy and Spectrometry. Elsevier, New York, USA.
2. Lublin FD, Reigold SC (1996) For the National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis. Defining the clinical course of multiple sclerosis: results of an international survey. Neurology 46(4): 907-911.
3. DeStefano N, Filippi M (2007) MR spectroscopy in multiple sclerosis. J Neuroimaging 17 Suppl 1: 315-355.
4. Y Ge (2006) Multiple Sclerosis: The Role of MR Imaging. AJNR Am J Neuroradiol 27(6): 1115-1176.
5. Falini A, Calabrese G, Filippi M, Orriga D, Lipari S, et al. (1998) Benign versus Secondary-Progressive Multiple Sclerosis: The Potential Role of Proton MR Spectroscopy in Defining the Nature of Disability. AJNR Am J Neuroradiol 19(2): 223-229.
6. Essig M, Anzalone N, Combs SE, Dörfler A, Lee SK, et al. (2012) MR Imaging of Neoplastic Central Nervous System Lesions: Review and Recommendations for Current Practice. AJNR Am J Neuroradiol 33(5): 803-817.
7. Majos C, Aguilera C, Alonso J, Julià-Sapé M, Castañer S, et al. (2009) Proton MR spectroscopy improves discrimination between tumor and pseudotumoral lesion in solid brain masses. AJNR Am J Neuroradiol 30(3): 544-551.
8. Saindane AM, Cha S, Law M, Xue X, Knopp EA, et al. (2002) Proton MR Spectroscopy of Tumeffective Demyelinating Lesions. AJNR Am J Neuroradiol 23(8): 1378-1386.
9. Saunders DE, Howe FA, van den Boogaart A, McLean MA, Griffiths JR, et al. (1995) Continuing ischaemic damage after acute middle cerebral artery infarction in humans demonstrated by short-echo proton spectroscopy. Stroke 26(6): 1007-1013.
10. Muñoz MS, Cvoor V, Armitage PA, Marshall I, Bastin ME, et al. (2008) Choline and creatine are not reliable denominators for calculating metabolite ratios in acute ischemic stroke. Stroke 39(9): 2467-2469.
11. Jonathan HG, Adam DW, Peter BB (2006) Clinical MR Neuroimaging: Diffusion, Perfusion and Spectroscopy. Cambridge University Press, New York, USA, 238(3): 852.
12. Barker PB, Breiter SN, Soher BJ, Chatham JC, Forder JR, et al. (1994) Quantitative proton spectroscopy of canine brain: in vivo and in vitro correlations. Magn Reson Med 32(2): 157-163.
13. Mathews VP, Barker PB, Blackband SJ, Chatham JC, Bryan RN (1995) Cerebral Metabolites in Patients with Acute and Subacute Strokes: Concentrations Determined by Quantitative Proton MR Spectroscopy. AJR Am J Roentgenol 165(3): 633-638.
14. Mader I, Rauer S, Goll P, Klose U (2008) 1H MR spectroscopy of inflammation, infection and ischemia of the brain. Eur J Radiol 67(2): 250-257.
15. Gupta RK, Vatsal DK, Husain N, Chawla S, Prasad KN (2001) Differentiation of Tuberculous from Pyogenic Brain Abscesses with In Vivo Proton MR Spectroscopy and Magnetization Transfer MR Imaging. AJNR Am J Neuroradiol 22(1): 1501-1509.
16. Chiang IC, Hsieh TJ, Chiu ML, Liu GC, Kuo YT, et al. (2009) Distinction between pyogenic brain abscess and necrotic brain tumour using 3-tesla MR spectroscopy, diffusion and perfusion imaging. Br J Radiol 82(982): 813-820.
17. Yue Q, Isobe T, Shibata Y, Anno I, Kawamura H, et al. (2008) New observations concerning the interpretation of magnetic resonance spectroscopy of meningioma. Eur Radiol 18(12): 2901-2911.
18. Andre E, Xu M, Yang D, Siow JK, Yeo TC, et al. (2006) MR spectroscopy in sinus mucouscule: N-acetyl mimics of brain N-acetylaspartate. AJNR Am J Neuroradiol 27(10): 2210-2213.
19. Howe FA, Barton SJ, Cudlip SA, Stubbs M, Saunders DE, et al. (2003) Metabolic profiles of human brain tumors using quantitative in vivo 1H magnetic resonance spectroscopy. Magn Reson Med 49(2): 223-232.
20. Majos C, Alonso J, Aguilera C, Serrallonga M, Pérez-Martín J, et al. (2003) Proton magnetic resonance spectroscopy [(1) H MRS] of human brain tumours: assessment of differences between tumour types and its applicability in brain tumour categorization. Eur Radiol 13(3): 582-591.
21. Lehnhardt FG, Bock C, Rohn G, Erneuts RL, Hoehn M (2005) Metabolic differences between primary and recurrent human brain tumors: a 1H NMR spectroscopic investigation. NMR Biomed 18(6): 371-382.
22. Crisi G (2011) (1) H MR Spectroscopy of Meningiomas at 3.0T: the Role of Glutamate-Glutamine Complex and Glutathione. Crisi G (2011) (1) H MR Spectroscopy of Meningiomas at 3.0T: the Role of Glutamate-Glutamine Complex and Glutathione. AJNR Am J Neuroradiol 24(6): 846-853.
23. Tugnoli V, Schenetti L, Mucci A, Parenti F, Cagnoli R, et al. (2003) Ex vivo HR-MAS MRS of human meningiomas: A comparison with in vivo 1H MR spectra. Int J Mol Med 18(5): 859-869.
24. Monléon D, Morales JM, Gonzalez-Darder J, Talamantes F, Cortés O, et al. (2008) Benign and Atypical Meningioma Metabolic Signatures by High-Resolution Magic-Angle Spinning Molecular Profiling. J Proteome Res 7(7): 2882-2888.
25. Qi ZG, Li YX, Wang Y, Geng DY, Li KC, et al. (2008) Lipid signal in
evaluation of intracranial meningiomas. Chin Med J (Engl) 121(23): 2415-2419.

26. Kousi E, Tsougos I, Fountas K, Theodorou K, Tsolaki E, et al. (2012) Distinct peak at 3.8 ppm observed by 3T MR spectroscopy in meningiomas, while nearly absent in high-grade gliomas and cerebral metastases. Mol Med Rep 5(4): 1011-1018.

27. Mikhail FC, Takakazu K, Kosaku A, Yako O, Takaei S, et al. (2009) Possible role of single-voxel 1 H-MRS in differential diagnosis of suprasellar tumors. J Neurooncol 91(2): 191-198.

28. Yoshioka Y, Yoshioka Y (1991) Utility of proton magnetic resonance spectroscopy in the diagnosis of human brain tumors. No Shinkei Geka 19(5): 421-427.

29. Sener RN (2001) Proton MR spectroscopy of craniopharyngiomas. Comput Med Imaging Graph 25(5): 417-422.

30. Righi V, Tognoli V, Mucci A, Bacci A, Bonora S, et al. (2012) MRS study of meningial hemangiopericytoma and edema: A comparison with meningothelial meningioma. Oncol Rep 28(4): 1461-1467.

31. Barba I, Moreno A, Martinez-Pérez I, Tate AR, Cabañas ME, et al. (2001) Magnetic resonance spectroscopy of brain hemangiopericytomas: high myoinositol concentrations and discrimination from meningiomas. J Neurosurg 94(1): 55-60.

32. Cho YD, Choi GH, Lee SP, Kim JK (2003) H-MRS metabolic patterns for distinguishing between meningiomas and other brain tumors. Magn Reson Imaging 21(6): 663-672.

33. Majés C, Juliá-Sapé M, Alonso J, Serrallonga M, Aguiler C, et al. (2004) Brain Tumor Classification by Proton MR Spectroscopy: Comparison of Diagnostic Accuracy at Short and Long TE. AJNR Am J Neuroradiol 25(10): 1696-1704.

34. Evanthia K, Ioannis T, Kapsalaki E (2013) Proton Magnetic Resonance Spectroscopic Evaluation of Glioma Grading at 3T: The Combined Role of the brain. Eur Radiol 19(8): 2049-2059.

35. Majós C, Juliá-Sapé M, Aguilera C, Mora R, Camins A, et al. (2009) Proton MR spectroscopic imaging. NMR Biomed 16(1): 12-18.

36. Hwang H, Egnaczyk GF, Ballard E, Dunn RS, Holland SK, et al. (1998) Proton MR spectroscopic characteristics of pediatric pilocytic astrocytomas. AJNR Am J Neuroradiol 19: 535-540.

37. Soares DP, Law M (2009) Magnetic resonance spectroscopy of the brain: review of metabolites and clinical applications. Clin Radiol 64(1): 12-21.

38. Yuh EL, Barkovich AJ, Gupta N (2009) Imaging of ependymomas: MRI and CT. Childs Nerv Syst 25(10): 1203-1213.

39. Ripkema M, Schuring J, van der Meulen Y, van der Graaf M, Bernsen A, et al. (2004) Taurine Detection by Proton Magnetic Resonance Spectroscopy. NMR Biomed 17(1): 12-18.

40. Majós C, Aguiler C, Cos M, Camins A, Candiotia AP, et al. (2009) In vivo proton magnetic resonance spectroscopy of intraventricular tumors of the brain. Eur Radiol 19(8): 2049-2059.

41. Kousi E, Tsougos I, Tsolaki E, Fountas KN, Theodorou K, et al. (2012) Spectroscopic Evaluation of Glioma Grading at 3T: The Combined Role of Short and Long TE. Scientific World Journal 2012: 546171.

42. Shimizu H, Kaube T, Tominaga T, Kayama T, Harra K, et al. (1996) Noninvasive evaluation of malignancy of brain tumors with proton MR spectroscopy. American Journal of Neuroradiology 17(4): 737-747.

43. Zheng Q, Liu H, Zhang K, Li C, Zhou G (2011) Zhou, Noninvasive evaluation of cerebral glioma grade by using multivoxel 3D proton MR spectroscopy. Magn Reson Imaging 29(1): 25-31.

44. Negendank WG, Sauter R, Brown TR, Evelhoch JL, Falini A, et al. (1996) Proton magnetic resonance spectroscopy in patients with glial tumors: a multicenter study. J Neurosurg 84(3): 449-458.

45. Kim IH, Chang KH, Na DG, Song IC, Kwon BJ, et al. (2006) 3T 1H-MR Spectroscopy in Grading of Cerebral Gliomas: Comparison of Short and Intermediate Echo Time Sequences. AJNR Am J Neuroradiol 27(7): 1412-1418.

46. Al-Okaili RN, Krejza J, Wang S, Woo JH, Melhem ER (2006) Woo and Elias R. Melhem. Advanced MR Imaging Techniques in the Diagnosis of Intraxial Brain Tumors in Adults. Radiographics 26 Suppl 1: S173-S189.

47. Castillo M, Smith JK, Kwock L (2000) Correlation of Myo-inositol Levels and Grading of Cerebral Astrocytomas. AJNR Am J Neuroradiol 21(9): 1645-1649.

48. Graves EE, Nelson SJ, Vigneron DB, Verhey L, McDermott M, et al. (2001) Serial Proton MR Spectroscopic Imaging of Recurrent Malignant Gliomas after Gamma Knife Radiosurgery. AJNR Am J Neuroradiol 22(4): 613-624.

49. Schlemmer HP, Bachtet P, Herfarth KK, Zuna I, Debuc J, et al. (2001) Proton MR Spectroscopic Evaluation of Suspicious Brain Lesions After Stereotactic Radiotherapy. AJNR Am J Neuroradiol 22(7): 1316-1324.

50. Möller-Hartmann W, Hermingshaus S, Kriigs T, Marquardt G, Lanfermann H, et al. (2002) Clinical application of proton magnetic resonance spectroscopy in the diagnosis of intracranial mass lesions. Neuroradiology 44(5): 371-381.

51. Server A, Jossefn S, Kulle B, Maehlen J, Schellhorn T, et al. (2010) Proton magnetic resonance spectroscopy in the distinction of high-grade cerebral gliomas from single metastatic brain tumors. Acta Radiol 51(3): 316-325.

52. Law M, Cha S, Knopp EA, Johnson G, Arnett J, et al. (2002) High-grade gliomas and solitary metastases: differentiation by using perfusion and proton spectroscopic MR imaging. Radiology 222(3): 715-721.

53. Sjabbek TE, Johansen R, Batten TF, Sonnewald U, Kivistä KD, et al. (2007) Metabolic profiling of human brain metastases using in vivo proton MR spectroscopy at 3T. BMC Cancer 7: 141.

54. Tsougos I, Svolos P, Kousi E, Fountas K, Theodorou K, et al. (2012) Differentiation of glioblastoma multiforme from metastatic brain tumor using proton magnetic resonance spectroscopy, diffusion and perfusion metrics at 3 T. Cancer Imaging 12: 423-436.

55. Chawla S, Zhang Y, Wang S, Chaudhary S, Chou C, et al. (2010) Proton magnetic resonance spectroscopy in differentiating glioblastomas from primary cerebral lymphomas and brain metastases. J Comput Assist Tomogr 34(6): 836-841.

56. Kinoshita Y, Yokota A (1997) Absolute Concentrations of Metabolites in Human Brain Tumors Using In Vitro Proton Magnetic Resonance Spectroscopy. NMR Biomed 10(1): 1-12.

57. Moreno-Torres A, Martinez-Pérez I, Baquero M, Campistol J, Capdevila A, et al. (2004) Taurine Detection by Proton Magnetic Resonance Spectroscopy in Medulloblastoma: Contribution to Noninvasive Differential Diagnosis with Cerebellar Astrocytoma. Neurosurgery 55(4): 824-829.

58. Kovaliky A, Panigrahy A, Krieger MD, Gonzalez-Gomez L, Ghugre N, et al. (2005) Untreated Pediatric Primitive Neuroectodermal Tumor in Vivo: Quantitation of Taurine with MR Spectroscopy. Radiology 236(3): 1020-1025.

59. Majós C, Alonso J, Aguilera C, Serrallonga M, Acebes JJ, et al. (2002) Adult Primitive Neuroectodermal Tumor: Proton MR Spectroscopic Findings with Possible Application for Differential Diagnosis. Radiology 225(2): 556-566.